Binding with the CLR/RAMP1 receptor increases the invasiveness and migration capacity of tumor cells, promotes epithelial–mesenchymal transition and metastases, and could represent possible therapeutic targets to be included in clinical trials [74,75]. This evidence concerns the gene DCLK3 and neoplasm.